| アブストラクト | Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors might increase the risk of intestinal obstruction, but real-world evidence for this severe adverse event is lacking. Thus, the objective of this study was to determine whether GLP-1 RAs and DPP-4 inhibitors are associated with an increased risk of intestinal obstruction compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors. We used the United Kingdom Clinical Practice Research Datalink and linked databases to assemble two new-user, active comparator cohorts (2013-2019). The first included 25,617 and 67,261 GLP-1 RA and SGLT-2 inhibitor users, respectively. The second included 131,927 and 40,615 DPP-4 inhibitor and SGLT-2 inhibitor users, respectively. Propensity score fine stratification weighted Cox proportional hazards models were fit to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of intestinal obstruction requiring hospitalization. GLP-1 RAs were associated with an increased risk of intestinal obstruction compared with SGLT-2 inhibitors (1.9 vs. 1.1 per 1,000 person-years, respectively; HR: 1.69, 95% CI: 1.04-2.74). The highest HR was observed after 1.6 years of use (HR: 3.48, 95% CI: 1.79-6.79). DPP-4 inhibitors were also associated with an increased risk (2.7 vs. 1.0 per 1,000 person-years; HR: 2.59, 95% CI: 1.52-4.42), with the highest HR observed after 1.8 years of use (HR: 9.53, 95% CI: 4.47-20.30). The number needed to harm after 1 year of use was 1,223 and 603 for GLP-1 RAs and DPP-4 inhibitors, respectively. In this large real-world study, GLP-1 RAs and DPP-4 inhibitors were associated with an increased risk of intestinal obstruction. |
|---|
| 投稿者 | Faillie, Jean-Luc; Yin, Hui; Yu, Oriana H Y; Herrero, Astrid; Altwegg, Romain; Renoux, Christel; Azoulay, Laurent |
|---|
| 組織名 | Department of Medical Pharmacology and Toxicology, CHU Montpellier University;Hospital, Montpellier, France.;UA11 Institute Desbrest of Epidemiology and Public Health, INSERM, University of;Montpellier, Montpellier, France.;Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital,;Montreal, Quebec, Canada.;Division of Endocrinology, Jewish General Hospital, Montreal, Quebec, Canada.;Department of Visceral Surgery, CHU Montpellier University Hospital, Montpellier,;France.;Department of Gastroenterology, CHU Montpellier University Hospital, Montpellier,;Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec,;Canada.;Department of Epidemiology, Biostatistics, and Occupational Health, McGill;University, Montreal, Quebec, Canada.;Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, |
|---|
